86953-81-3Relevant articles and documents
Backbone-Modified C2-Symmetrical Chiral Bisphosphine TMS-QuinoxP*: Asymmetric Borylation of Racemic Allyl Electrophiles
Imamoto, Tsuneo,Ito, Hajime,Iwamoto, Hiroaki,Ozawa, Yu,Takenouchi, Yuta
supporting information, p. 6413 - 6422 (2021/05/31)
A new C2-symmetrical P-chirogenic bisphosphine ligand with silyl substituents on the ligand backbone, (R,R)-5,8-TMS-QuinoxP*, has been developed. This ligand showed higher reactivity and enantioselectivity for the direct enantioconvergent borylation of cy
Hydrozirconation of four-, five-, six- and seven-membered N-alkoxycarbonyl lactams to lactamols
Piperno, Anna,Carnovale, Caterina,Giofr, Salvatore V.,Iannazzo, Daniela
supporting information; experimental part, p. 6880 - 6882 (2012/02/05)
A general, practical, and efficient reduction of four-, five-, six- and, seven-membered N-alkoxycarbonyl lactams to the aldehyde oxidation state is reported. The reduction methodology involves the hydrozirconation reaction by Cp2Zr(H)Cl under m
Pyrrolopyrimidines as therapeutic agents
-
, (2008/06/13)
Chemical compounds having structural formula I and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatiod arthritis, disorders of the immune system, trasplant refections and imflammatory disorders.